Last quarter (Q ), Pear Therapeutics's total revenue was $2.56M, an increase of 94.32% from the same quarter last year. In Q, Pear Therapeutics's net income was $-26.37M. See Pear Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ 12.69M	$ 12.69M	$ 4.21M	$ 9.38M	$ 32.56M
Cost of Revenue	$ 8.18M	$ 8.18M	$ 5.23M	$ 1.72M	$ 998.00K
Gross Profit	$ 4.51M	$ 4.51M	$ -1.02M	$ 7.67M	$ 31.56M
Operating Expense	$ 127.86M	$ 127.86M	$ 104.66M	$ 84.31M	$ 63.17M
Operating Income	$ -123.35M	$ -123.35M	$ -105.69M	$ -76.64M	$ -31.60M
Net Non Operating Interest Income Expense	$ -3.89M	$ -3.89M	$ -4.14M	$ -1.77M	$ 1.42M
Other Income Expense	$ 51.75M	$ 51.75M	$ 44.69M	$ -18.61M	$ 20.85M
Pretax Income	$ -75.49M	$ -75.49M	$ -65.14M	$ -97.02M	$ -9.33M
Tax Provision	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	$ -75.49M	$ -75.49M	$ -65.14M	$ -108.08M	$ -9.33M
Basic EPS	$ -0.54	$ -0.54	$ -0.57	$ -0.78	$ -0.07
Diluted EPS	$ -0.54	$ -0.54	$ -0.57	$ -0.78	$ -0.07
Basic Average Shares	$ 554.82M	$ 138.71M	$ 113.33M	$ 137.80M	$ 137.80M
Diluted Average Shares	$ 563.95M	$ 138.71M	$ 113.33M	$ 137.80M	$ 137.80M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	$ 136.04M	$ 136.04M	$ 109.89M	$ 86.03M	$ 64.17M
Net Income From Continuing And Discontinued Operation	$ -75.49M	$ -75.49M	$ -65.14M	$ -97.02M	$ -9.33M
Normalized Income	$ -79.67M	$ -127.24M	$ -111.88M	$ -95.23M	$ -29.64M
Interest Expense	-	-	-	$ 2.56M	-
EBIT	$ -123.35M	$ -123.35M	$ -105.69M	$ -76.64M	$ -31.60M
EBITDA	$ -117.65M	$ -117.65M	$ -103.43M	$ -76.21M	$ -31.39M

Currency in USD

Pear Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing